TABLE 3.

Serum Levels Changes of TNF related Biomarkers during belimumab treatment.

	T0 (n = 21)	T6 (n = 21)	T12 (n = 21)	p T0 vs. T6	p T0 vs. T12	p T6 vs T12
BAFF (pg/ml)	444.8 (134.4–1,091.2)	366.5 (201.5–722.7)	334.7 (209.2–589.9)	0.0547	0.0215	0.8124
APRIL (pg/ml)	2053.3 (1,369.2–3,407.9)	2,085.3 (1,346.8–3,268.5)	2,117.6 (1,368.1–3,862.2)	0.1678	0.4304	0.9273
sTACI (pg/ml)	1,096.5 (397.3–6,599.9)	782.3 (181.7–4,011.3)	777.6 (243.0–4,610.9)	0.0003	0.0006	0.0215
sBCMA (ng/ml)	7,982.7 (6,099.2–12,114.7)	7,954.4 (5,523.5–11,303.0)	7,437.8 (5,771.4–9,319.0)	0.0319	0.0010	0.1054
sCD40L (pg/ml)	1,817.3 (703.2–10,754.0)	1,243.1 (522.2–4,721.5)	1,326.5 (522.2–5,999.5)	0.0005	0.0136	0.0759
TWEAK (pg/ml)	1,381.3 (938.9–10,656.5)	1,446.8 (815.5–6,671.6)	1,365.2 (812.0–6,151.8)	0.0010	0.0020	0.1327

Data are expressed as median (10th–90th percentile). In bold p ≤ 0.050. BAFF: B cell activating factor; APRIL: a proliferation-inducing ligand; sTACI: soluble transmembrane activator and calcium-modulator and cyclophilin ligand interactor; sBCMA, soluble B cell maturation antigen; sCD40L: soluble CD40 ligand; TWEAK: TNF-related weak inducer of apoptosis.